Karen Akinsanya - 05 Mar 2026 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role: President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Signature: /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Issuer symbol: SDGR
Transactions as of: 05 Mar 2026
Net transactions value: -$17,625
Form type: 4
Filing time: 06 Mar 2026, 17:27:15 UTC
Previous filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Akinsanya Karen	President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships	C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK	/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya	06 Mar 2026	0001797672

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SDGR	Common Stock	Sale	$17,625	-1,366	-1.9%	$12.90	69,956	05 Mar 2026	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.71 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) of this Form 4.
F3	Includes 63,545 unvested RSUs

Remarks:

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships